Tesamorelin
most data
The Dose Guy’s verdictAug 28, 20264 sources
Tesamorelin is the only GHRH analog with a current FDA approval and real trial data, and for its approved job, cutting visceral fat in people with HIV, the receipts are solid. The catch: most buyers are not running it for HIV lipodystrophy, they want general recomp, and for that the data is borrowed, not earned. It is also daily, expensive, and the fat comes back when you stop. If visceral fat is the specific target, this is the one with a regulatory stamp behind it. For general GH-axis work, CJC-1295 plus ipamorelin does the broader job for less.
What it is
A GHRH analog, the same class as CJC-1295, meaning it tells your pituitary to release growth hormone rather than supplying the hormone directly. Tesamorelin is a modified version of the full 44-amino-acid GHRH molecule, stabilized against the enzyme that breaks natural GHRH down in minutes. It is approved specifically for reducing the belly fat that builds up in people on long-term HIV treatment, a visible side effect of certain antiretrovirals. Outside that lane, people run it for the same reasons they run any GHRH analog: body composition, recovery, and the hope that elevated GH delivers what the mechanism promises.
The mechanism is shared with CJC-1295. The difference is that tesamorelin has trial data in one specific population and a price tag to match. If you are paying more, you are paying for the evidence, not a different biological action.
What the research shows
Real trials and a clear ceiling. The evidence is deep for visceral fat reduction in HIV and thin for everything else:
Realistic protocols
The approved dose is 2 mg subcutaneously, once daily, and that is what most people run. It is a fixed dose, not a titration game, because the trials used 2 mg flat and that is where the data lives. Pin it on an empty stomach, because food blunts the GH pulse. The trials dosed in the morning. Some people run it pre-bed instead, riding the overnight GH surge the way CJC-1295 and sermorelin are run. A daily injection for six months or more is a routine, not a course. Build it into something that sticks.
The cost conversation is the real protocol conversation. Tesamorelin is expensive compared to CJC-1295 and ipamorelin, and it is a daily compound with no off days in the approved regimen. If the specific target is visceral belly fat, especially if imaging has confirmed it, the trial data supports the investment. If the goal is general GH-axis support for recovery and body composition, the CJC-1295 plus ipamorelin stack does the same mechanistic job at a fraction of the price without an approval to cite.
Side effects
A well-documented side profile from real trials, milder than most GH-axis compounds at this dose:
